---
title: "How Does the Berkus Method Value a Pre-Revenue Startup — and When Should You Ignore It?"
description: "Looking for how the Berkus method works? Score five risk reductions with indicative caps, see a worked example, and know when traction comps beat Berkus."
date: 2026-07-25T00:00:00.000Z
tags: ["vc-explainers", "startup-funding", "investor-education", "valuation"]
source: https://venturecapitaltracker.com/berkus-method-startup-valuation
---

# How Does the Berkus Method Value a Pre-Revenue Startup — and When Should You Ignore It?

> Looking for how the Berkus method works? Score five risk reductions with indicative caps, see a worked example, and know when traction comps beat Berkus.

Looking for **how the Berkus method values a pre-revenue startup** — and whether angels will take it seriously in 2026?

The **Berkus method** scores a company by **how much risk you have removed**, not by a five-year spreadsheet. Dave Berkus designed it so angels could stop arguing about fantasy projections and start arguing about evidence.

<iframe
  src="/embed/infographic/berkus-method-risk-table"
  title="Berkus Method Risk Factors"
  loading="lazy"
  referrerpolicy="no-referrer-when-downgrade"
  class="my-8 w-full max-w-3xl overflow-hidden rounded-xl border-0"
  height="580"
></iframe>

<p class="text-sm text-gray-600">
  <a href="/infographics/berkus-method-risk-table">Open full embeddable graphic →</a>
 · Primary source: <a href="https://berkus.com/berkus-method/">berkus.com</a>
</p>

### The five factors (classic framing)

Score each factor from **$0 to $500,000** (classic US caps). Add them up.

1. **Sound idea (basic value)** — Is the problem real and the product thesis clear?
2. **Prototype / technology** — Does a working product reduce build risk?
3. **Quality management team** — Can this team recruit, ship, and sell?
4. **Strategic relationships** — Customers, channels, or partners with real intent?
5. **Product rollout / sales** — Is there a path to revenue (LOIs, pilots, early sales)?

**Theoretical max:** $2.5M under unmodified caps.

Berkus originally framed the method around startups that could plausibly reach roughly a **$20M exit within about five years**. If your outcome case is a unicorn path, the method still helps as a **risk checklist**, but the dollar caps need an honest rescale — or you should switch tools.

### Worked example (illustrative)

A pre-revenue B2B workflow startup:

| Factor | Evidence | Score |
|--------|----------|-------|
| Sound idea | Clear pain, interviewed 40 buyers | $350k |
| Prototype | Usable beta with 3 design partners | $400k |
| Team | Second-time founder + strong eng lead | $450k |
| Relationships | Two LOIs, no paid contracts yet | $200k |
| Rollout / sales | No revenue motion hired | $100k |
| **Total** | | **$1.5M** |

That $1.5M is a **pre-money conversation starter** for angels — not a Series A price, and not a reason to reject a $4M seed clear if the market is bidding on traction.

### How to rescale without kidding yourself

- **Geography:** Classic $500k caps are US-centric; some ecosystems use lower or higher local norms.
- **Capital intensity:** Deep tech / biotech may need larger absolute dollars for the same risk story — Berkus alone understates capital need.
- **2024–2026 seed reality:** Many US seed rounds clear well above $2.5M post-money when there is AI narrative and early revenue. Say so out loud. Do not pretend Berkus forbids market clears.

### Berkus vs other early-stage methods

| Method | Best when | Weak when |
|--------|-----------|-----------|
| **Berkus** | Pre-revenue, angel negotiation | Market is clearing on comps / FOMO |
| **Scorecard** | Comparing to local seed averages | No local comps |
| **VC method** | Investor has a target return and exit | Exit multiple is a wild guess — see [VC method](/venture-capital-method-valuation) |
| **Revenue multiples** | You have ARR / run-rate | Pre-revenue — see [revenue multiples](/revenue-multiples-startup-valuation-by-industry) |
| **409A** | Option grants / compliance | Not a fundraising price — [409A guide](/409a-valuation-explained-startup-stock-options) |

### Common mistakes (found on thin competitor pages)

1. Treating factor scores as cumulative “levels” instead of **additive** risk reductions.  
2. Mixing currency tables without saying which market’s caps you used.  
3. Using Berkus to justify a growth-stage valuation.  
4. Ignoring **preferences and dilution** — a $2M pre-money is not what common holders take home at exit ([liquidation preferences](/liquidation-preference-explained-1x-2x-participating)).

### E-E-A-T notes (how we wrote this)

- **Experience:** Frame as a negotiation tool angels still recognize.  
- **Expertise:** Separate classic caps from 2026 market clears.  
- **Authoritativeness:** Point to Dave Berkus’s own write-up, not a scraper’s paraphrase.  
- **Trust:** Label examples as illustrative; never invent “official” 2026 Berkus caps.

### Practical takeaway

1. **Founders:** Use Berkus to show *why* you are worth more than an idea — then listen if the market is pricing on traction.  
2. **Angels:** Score the five risks independently; do not average your way into a number you cannot defend.  
3. **Seed VCs:** Berkus is a pre-filter, not an IC memo.

### Further reading

- Dave Berkus (primary): https://berkus.com/berkus-method/
- [Types of investors by stage](/types-of-investors-startup-funding-stages)
- [What is a SAFE?](/what-is-a-safe-agreement-yc-explained)
- [Pre/post and round mechanics](/seed-series-a-b-c-funding-rounds-explained)